Search
Advertisement
Indian Pharma Sector Analysis: Mid-Teens Growth, Hospitals And Price-Control Risks

Indian Pharma Sector Analysis: Mid-Teens Growth, Hospitals And Price-Control Risks

Sakshi Batra
Sakshi Batra
  • New Delhi,
  • Nov 16, 2026,
  • Updated Nov 16, 2026, 1:03 PM IST

 

The pharma sector emerged as one of the best-performing sectors in the previous Samvat year, delivering 24% returns. But does the rally have more room to run? Chakri Lokapriya, Managing Partner, RSB LLP, shares his outlook on pharmaceutical companies, hospitals, diagnostics and CDMOs in the new Samvat year. While traditional pharma companies are expected to maintain mid-teens growth, product innovation could drive individual companies forward. The discussion also highlights the potential impact of government price controls on hospital and diagnostic companies, and why valuations remain a key consideration for investors looking at the healthcare space.